Maria Isabel Belizario, Julius Garcia Gatmaitan, Johannes Dayrit
Unlabelled: Pigmentary disorders have been implicated in causing psychosocial turmoil in patients as they can cause some degree of cosmetic disfigurement. Lichen planus pigmentosus (LPP) presents as ashy, dermatosis-like eruptions on sun-exposed areas, particularly on the head, neck, and earlobes. On the other hand, vitiligo is a chronic disorder that appears as depigmented patches on the skin. A 61-year-old man with Fitzpatrick skin phototype IV presented to us initially with LPP but eventually also developed vitiligo. The patient was treated with low-dose oral isotretinoin for LPP and topical tacrolimus 0.1% ointment for both LPP and vitiligo with a good clinical outcome. One case of segmental vitiligo and zosteriform LPP, affecting a 22-year-old Indian woman, has been previously reported in the English-language literature. An autoimmune etiology that causes melanocytorrhagy may be a plausible hypothesis for the coexistence of these 2 conditions.
{"title":"Lichen Planus Pigmentosus and Vitiligo in a 61-Year-Old Filipino Man: Case Report.","authors":"Maria Isabel Belizario, Julius Garcia Gatmaitan, Johannes Dayrit","doi":"10.2196/50401","DOIUrl":"10.2196/50401","url":null,"abstract":"<p><strong>Unlabelled: </strong>Pigmentary disorders have been implicated in causing psychosocial turmoil in patients as they can cause some degree of cosmetic disfigurement. Lichen planus pigmentosus (LPP) presents as ashy, dermatosis-like eruptions on sun-exposed areas, particularly on the head, neck, and earlobes. On the other hand, vitiligo is a chronic disorder that appears as depigmented patches on the skin. A 61-year-old man with Fitzpatrick skin phototype IV presented to us initially with LPP but eventually also developed vitiligo. The patient was treated with low-dose oral isotretinoin for LPP and topical tacrolimus 0.1% ointment for both LPP and vitiligo with a good clinical outcome. One case of segmental vitiligo and zosteriform LPP, affecting a 22-year-old Indian woman, has been previously reported in the English-language literature. An autoimmune etiology that causes melanocytorrhagy may be a plausible hypothesis for the coexistence of these 2 conditions.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e50401"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annie Chang, Jade Young, Andrew Para, Angela Lamb, Nicholas Gulati
Unlabelled: This study investigates the application of ChatGPT, an artificial intelligence tool, in providing information on skin toxicities associated with cancer treatments, highlighting that while ChatGPT can serve as a valuable resource for clinicians, its use for patient education requires careful consideration due to the complex nature of the information provided.
{"title":"Efficacy of ChatGPT in Educating Patients and Clinicians About Skin Toxicities Associated With Cancer Treatment.","authors":"Annie Chang, Jade Young, Andrew Para, Angela Lamb, Nicholas Gulati","doi":"10.2196/54919","DOIUrl":"10.2196/54919","url":null,"abstract":"<p><strong>Unlabelled: </strong>This study investigates the application of ChatGPT, an artificial intelligence tool, in providing information on skin toxicities associated with cancer treatments, highlighting that while ChatGPT can serve as a valuable resource for clinicians, its use for patient education requires careful consideration due to the complex nature of the information provided.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e54919"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexis Coican, Nathaniel A Marroquin, Alexa Carboni, Sara Holt, Morgan Zueger
Unlabelled: We found that third-party apps such as Figure 1 were used predominantly by nondermatologist medical personnel for collaboration in medical decision-making related to dermatologic conditions conducted with other health care providers. This finding calls attention to the need for more readily available resources for nondermatologist health care providers encountering patients with skin-related conditions, with the added benefits of trained dermatologists being allies on such medical app platforms, and the platform allowing for recognition of instances when additional consultation or referral to trained dermatologists for more complex cases is appropriate.
{"title":"How Dermatologists Can Aid Nondermatologic Professionals Using the <i>Figure 1</i> App: Case Analysis.","authors":"Alexis Coican, Nathaniel A Marroquin, Alexa Carboni, Sara Holt, Morgan Zueger","doi":"10.2196/60500","DOIUrl":"https://doi.org/10.2196/60500","url":null,"abstract":"<p><strong>Unlabelled: </strong>We found that third-party apps such as Figure 1 were used predominantly by nondermatologist medical personnel for collaboration in medical decision-making related to dermatologic conditions conducted with other health care providers. This finding calls attention to the need for more readily available resources for nondermatologist health care providers encountering patients with skin-related conditions, with the added benefits of trained dermatologists being allies on such medical app platforms, and the platform allowing for recognition of instances when additional consultation or referral to trained dermatologists for more complex cases is appropriate.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e60500"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alicia Podwojniak, Joseph Flemming, Isabella J Tan, Hira Ghani, Zachary Neubauer, Anne Jones
Background: Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSIIs) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance.
Objective: This systematic review aims to explore the current literature surrounding dermatologic complications of CGM and CSII as well as the impact on patient outcomes.
Methods: A systematic review of the literature was carried out using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines using 5 online databases. Included articles were those containing primary data relevant to human participants and adverse reactions to CGM and CSII devices in pediatric populations, of which greater than 50% of the sample size were aged 0-21 years. Qualitative analysis was chosen due to the heterogeneity of outcomes.
Results: Following the application of exclusion criteria, 25 studies were analyzed and discussed. An additional 5 studies were identified after the initial search and inclusion. The most common complication covered is contact dermatitis, with 13 identified studies. Further, 7 studies concerned lipodystrophies, 5 covered nonspecific cutaneous changes, 3 covered unique cutaneous findings such as granulomatous reactions and panniculitis, and 2 discussed user acceptability.
Conclusions: The dermatologic complications of CGM and CSII pose a potential risk to long-term glycemic control in T1D, especially in young patients where skin lesions can lead to discontinuation. Increased manufacturer transparency is critical and further studies are needed to expand upon the current preventative measures such as device site rotation and steroid creams, which lack consistent effectiveness.
{"title":"Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.","authors":"Alicia Podwojniak, Joseph Flemming, Isabella J Tan, Hira Ghani, Zachary Neubauer, Anne Jones","doi":"10.2196/59824","DOIUrl":"https://doi.org/10.2196/59824","url":null,"abstract":"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSIIs) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance.</p><p><strong>Objective: </strong>This systematic review aims to explore the current literature surrounding dermatologic complications of CGM and CSII as well as the impact on patient outcomes.</p><p><strong>Methods: </strong>A systematic review of the literature was carried out using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines using 5 online databases. Included articles were those containing primary data relevant to human participants and adverse reactions to CGM and CSII devices in pediatric populations, of which greater than 50% of the sample size were aged 0-21 years. Qualitative analysis was chosen due to the heterogeneity of outcomes.</p><p><strong>Results: </strong>Following the application of exclusion criteria, 25 studies were analyzed and discussed. An additional 5 studies were identified after the initial search and inclusion. The most common complication covered is contact dermatitis, with 13 identified studies. Further, 7 studies concerned lipodystrophies, 5 covered nonspecific cutaneous changes, 3 covered unique cutaneous findings such as granulomatous reactions and panniculitis, and 2 discussed user acceptability.</p><p><strong>Conclusions: </strong>The dermatologic complications of CGM and CSII pose a potential risk to long-term glycemic control in T1D, especially in young patients where skin lesions can lead to discontinuation. Increased manufacturer transparency is critical and further studies are needed to expand upon the current preventative measures such as device site rotation and steroid creams, which lack consistent effectiveness.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e59824"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Macy Haight, Hayden R Jacobs, Sarah K Boltey, Kelly A Murray, Micah Hartwell
Unlabelled: Through Jimmy Buffett's unfortunate battle with lymphoma originating from Merkel cell carcinoma and subsequent media coverage of his death, public interest in skin cancer, Merkel cell carcinoma, and the health effects of sunlight exposure increased, as evidenced by our results.
{"title":"US Public Interest in Merkel Cell Carcinoma Following Jimmy Buffett's Death and Implications for Continued Health Advocacy: Infodemiology Study of Google Trends.","authors":"Macy Haight, Hayden R Jacobs, Sarah K Boltey, Kelly A Murray, Micah Hartwell","doi":"10.2196/60282","DOIUrl":"10.2196/60282","url":null,"abstract":"<p><strong>Unlabelled: </strong>Through Jimmy Buffett's unfortunate battle with lymphoma originating from Merkel cell carcinoma and subsequent media coverage of his death, public interest in skin cancer, Merkel cell carcinoma, and the health effects of sunlight exposure increased, as evidenced by our results.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e60282"},"PeriodicalIF":0.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeemin Kang, Mindy D Szeto, Lois Suh, Jadesola T Olayinka, Robert P Dellavalle
Unlabelled: TikTok is a social media platform that can educate users about dermatology, but this longitudinal analysis of skin of color-related TikTok hashtags from 2021 to 2022 suggests that nondermatologist influencers continue to dominate content creation, highlighting the need for more participation from board-certified dermatologists to actively counter misinformation and address potential disparities in skin-of-color health care.
{"title":"Popular Skin-of-Color Dermatology Social Media Hashtags on TikTok From 2021 to 2022: Content Analysis.","authors":"Jeemin Kang, Mindy D Szeto, Lois Suh, Jadesola T Olayinka, Robert P Dellavalle","doi":"10.2196/50408","DOIUrl":"10.2196/50408","url":null,"abstract":"<p><strong>Unlabelled: </strong>TikTok is a social media platform that can educate users about dermatology, but this longitudinal analysis of skin of color-related TikTok hashtags from 2021 to 2022 suggests that nondermatologist influencers continue to dominate content creation, highlighting the need for more participation from board-certified dermatologists to actively counter misinformation and address potential disparities in skin-of-color health care.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e50408"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Femke van Sinderen, Anne P Langermans, Andre W Kushniruk, Elizabeth M Borycki, Monique M Jaspers, Linda W Peute
<p><strong>Background: </strong>Teledermoscopy has demonstrated benefits such as decreased costs and enhanced access to dermatology care for skin cancer detection. However, the heterogeneity among teledermoscopy studies hinders the systematic reviews' synopsis of diagnostic outcomes, impeding trust and adoption in general practice and limiting overall health care benefits.</p><p><strong>Objective: </strong>This study aims to improve understanding and standardization of teledermoscopy diagnostic studies, by identifying and categorizing study characteristics contributing to heterogeneity. Subsequently, the variability and consistency of these characteristics were assessed.</p><p><strong>Methods: </strong>A review of systematic reviews regarding the diagnostic outcomes of teledermoscopy was performed to discern reported study characteristics contributing to heterogeneity. These characteristics were thematically grouped into 3 domains (population, index test, and reference standard), forming a data extraction framework. A scoping review on teledermoscopy diagnostic outcomes studies was performed, guided by the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) checklist. Data pertaining to study characteristics from included studies were extracted and analyzed through descriptive content analysis. Systematic reviews' reference lists validated the scoping review query.</p><p><strong>Results: </strong>The literature search yielded 4 systematic reviews, revealing 15 heterogeneous studies across the population, index test, and reference standard domains. The scoping review identified 49 studies, with 27 overlapping with the systematic reviews. Population characteristics varied, with one-third (16/49, 33%) of studies reporting fewer than 100 samples; most studies (41/49, 84%) reported on the type of lesion, and most (20/49, 41%) teledermoscopy consultations took place in secondary care. One-fifth (11/49, 22%) did not describe inclusion or exclusion criteria, or the criteria varied highly. Index test characteristics showed differences in clinical expertise, profession, and training in dermatoscopic photography, and 59% (29/49) did not report on 1 or more index test characteristics. Image quality and clinical information reporting likewise varied. Reference standard characteristics involved teledermatologists' assessment, but 16 studies did not report teledermatologists' experience levels. Most studies (26/49, 53%) used histopathology as a gold standard.</p><p><strong>Conclusions: </strong>The heterogeneity in the population, index tests, and reference standard domains across teledermoscopy diagnostic outcome studies underscores the need for standardized reporting. This hinders the synopsis of teledermoscopy diagnostic outcomes in systematic reviews and limits the integration of research results into practice. Adopting a (tailored) STARD (Standards for Reporting Diagnostic Accuracy Studies) checklis
{"title":"Challenges in Teledermoscopy Diagnostic Outcome Studies: Scoping Review of Heterogeneous Study Characteristics.","authors":"Femke van Sinderen, Anne P Langermans, Andre W Kushniruk, Elizabeth M Borycki, Monique M Jaspers, Linda W Peute","doi":"10.2196/60346","DOIUrl":"10.2196/60346","url":null,"abstract":"<p><strong>Background: </strong>Teledermoscopy has demonstrated benefits such as decreased costs and enhanced access to dermatology care for skin cancer detection. However, the heterogeneity among teledermoscopy studies hinders the systematic reviews' synopsis of diagnostic outcomes, impeding trust and adoption in general practice and limiting overall health care benefits.</p><p><strong>Objective: </strong>This study aims to improve understanding and standardization of teledermoscopy diagnostic studies, by identifying and categorizing study characteristics contributing to heterogeneity. Subsequently, the variability and consistency of these characteristics were assessed.</p><p><strong>Methods: </strong>A review of systematic reviews regarding the diagnostic outcomes of teledermoscopy was performed to discern reported study characteristics contributing to heterogeneity. These characteristics were thematically grouped into 3 domains (population, index test, and reference standard), forming a data extraction framework. A scoping review on teledermoscopy diagnostic outcomes studies was performed, guided by the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) checklist. Data pertaining to study characteristics from included studies were extracted and analyzed through descriptive content analysis. Systematic reviews' reference lists validated the scoping review query.</p><p><strong>Results: </strong>The literature search yielded 4 systematic reviews, revealing 15 heterogeneous studies across the population, index test, and reference standard domains. The scoping review identified 49 studies, with 27 overlapping with the systematic reviews. Population characteristics varied, with one-third (16/49, 33%) of studies reporting fewer than 100 samples; most studies (41/49, 84%) reported on the type of lesion, and most (20/49, 41%) teledermoscopy consultations took place in secondary care. One-fifth (11/49, 22%) did not describe inclusion or exclusion criteria, or the criteria varied highly. Index test characteristics showed differences in clinical expertise, profession, and training in dermatoscopic photography, and 59% (29/49) did not report on 1 or more index test characteristics. Image quality and clinical information reporting likewise varied. Reference standard characteristics involved teledermatologists' assessment, but 16 studies did not report teledermatologists' experience levels. Most studies (26/49, 53%) used histopathology as a gold standard.</p><p><strong>Conclusions: </strong>The heterogeneity in the population, index tests, and reference standard domains across teledermoscopy diagnostic outcome studies underscores the need for standardized reporting. This hinders the synopsis of teledermoscopy diagnostic outcomes in systematic reviews and limits the integration of research results into practice. Adopting a (tailored) STARD (Standards for Reporting Diagnostic Accuracy Studies) checklis","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e60346"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Deonna Ackermann, Jolyn Hersch, Dana Jordan, Emily Clinton-Gray, Karen Bracken, Monika Janda, Robin Turner, Katy Bell
<p><strong>Background: </strong>Limited data exist on the motivations and expectations of participants when enrolling in dermatology clinical trials, including melanoma early detection trials. Understanding participant motivators for research engagement has been identified as a prioritized area for trial methodology research.</p><p><strong>Objective: </strong>The study aimed to determine motivators of participation and expectations from trial involvement among patients enrolled in the MEL-SELF randomized clinical trial of patient-led surveillance for new or recurrent melanoma.</p><p><strong>Methods: </strong>The MEL-SELF trial is recruiting patients previously treated for localized melanoma, who own a smartphone, have a partner to assist with skin self-examination (SSE), and attend routinely scheduled follow-up at specialist and primary care skin clinics in Australia. We evaluated responses from the first 100 randomized participants to 2 open-ended questions about their motivations and expectations for participating in the trial, administered through the internet-based baseline questionnaire. A total of 3 coders independently coded the free-text responses and resolved discrepancies through consensus. Qualitative content analysis by an iterative process was used to group responses into themes. Responses from potential participants who were not randomized and the 404 participants randomized subsequently into the trial, were also checked for new themes. Coding and analysis were conducted in Microsoft Excel.</p><p><strong>Results: </strong>Out of the 100 survey participants, 98 (98%) answered at least 1 of the 2 questions. Overall, responses across the motivation and expectation items indicated 3 broad themes: community benefit, perceived personal benefit, and trusting relationship with their health care provider. The most common motivators for participation were related to community benefit. These included progressing medical research, benefitting future melanoma patients who may have similar experiences, and broader altruistic sentiments such as "helping others" or "giving back." The most common expectations from the trial related to personal benefit. These included perceived improved outcomes such as earlier diagnosis and treatment, access to additional care, and increased self-empowerment to take actions themselves that benefit their health. Patients expressed a desire to gain health-related knowledge and skills and were interested in the potential advantages of teledermatology. There were no new themes in responses from those who were not randomized or were randomized subsequent to the first 100.</p><p><strong>Conclusions: </strong>We report a tailorable, patient-focused approach to identify drivers of research engagement in clinical research. Clinical trials offer an opportunity to collate a substantial evidence base on determinants of research participation and to identify context-specific factors. Results from the MEL-SELF trial emphasized no
{"title":"Participant Motivators and Expectations in the MEL-SELF Randomized Clinical Trial of Patient-Led Surveillance for Recurrent Melanoma: Content Analysis of Survey Responses.","authors":"Deonna Ackermann, Jolyn Hersch, Dana Jordan, Emily Clinton-Gray, Karen Bracken, Monika Janda, Robin Turner, Katy Bell","doi":"10.2196/58136","DOIUrl":"10.2196/58136","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist on the motivations and expectations of participants when enrolling in dermatology clinical trials, including melanoma early detection trials. Understanding participant motivators for research engagement has been identified as a prioritized area for trial methodology research.</p><p><strong>Objective: </strong>The study aimed to determine motivators of participation and expectations from trial involvement among patients enrolled in the MEL-SELF randomized clinical trial of patient-led surveillance for new or recurrent melanoma.</p><p><strong>Methods: </strong>The MEL-SELF trial is recruiting patients previously treated for localized melanoma, who own a smartphone, have a partner to assist with skin self-examination (SSE), and attend routinely scheduled follow-up at specialist and primary care skin clinics in Australia. We evaluated responses from the first 100 randomized participants to 2 open-ended questions about their motivations and expectations for participating in the trial, administered through the internet-based baseline questionnaire. A total of 3 coders independently coded the free-text responses and resolved discrepancies through consensus. Qualitative content analysis by an iterative process was used to group responses into themes. Responses from potential participants who were not randomized and the 404 participants randomized subsequently into the trial, were also checked for new themes. Coding and analysis were conducted in Microsoft Excel.</p><p><strong>Results: </strong>Out of the 100 survey participants, 98 (98%) answered at least 1 of the 2 questions. Overall, responses across the motivation and expectation items indicated 3 broad themes: community benefit, perceived personal benefit, and trusting relationship with their health care provider. The most common motivators for participation were related to community benefit. These included progressing medical research, benefitting future melanoma patients who may have similar experiences, and broader altruistic sentiments such as \"helping others\" or \"giving back.\" The most common expectations from the trial related to personal benefit. These included perceived improved outcomes such as earlier diagnosis and treatment, access to additional care, and increased self-empowerment to take actions themselves that benefit their health. Patients expressed a desire to gain health-related knowledge and skills and were interested in the potential advantages of teledermatology. There were no new themes in responses from those who were not randomized or were randomized subsequent to the first 100.</p><p><strong>Conclusions: </strong>We report a tailorable, patient-focused approach to identify drivers of research engagement in clinical research. Clinical trials offer an opportunity to collate a substantial evidence base on determinants of research participation and to identify context-specific factors. Results from the MEL-SELF trial emphasized no","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e58136"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Richard Barlow, Anthony Bewley, Maria Angeliki Gkini
Background: Artificial intelligence (AI) has many applications in numerous medical fields, including dermatology. Although the majority of AI studies in dermatology focus on skin cancer, there is growing interest in the applicability of AI models in inflammatory diseases, such as psoriasis. Psoriatic disease is a chronic, inflammatory, immune-mediated systemic condition with multiple comorbidities and a significant impact on patients' quality of life. Advanced treatments, including biologics and small molecules, have transformed the management of psoriatic disease. Nevertheless, there are still considerable unmet needs. Globally, delays in the diagnosis of the disease and its severity are common due to poor access to health care systems. Moreover, despite the abundance of treatments, we are unable to predict which is the right medication for the right patient, especially in resource-limited settings. AI could be an additional tool to address those needs. In this way, we can improve rates of diagnosis, accurately assess severity, and predict outcomes of treatment.
Objective: This study aims to provide an up-to-date literature review on the use of AI in psoriatic disease, including diagnostics and clinical management as well as addressing the limitations in applicability.
Methods: We searched the databases MEDLINE, PubMed, and Embase using the keywords "AI AND psoriasis OR psoriatic arthritis OR psoriatic disease," "machine learning AND psoriasis OR psoriatic arthritis OR psoriatic disease," and "prognostic model AND psoriasis OR psoriatic arthritis OR psoriatic disease" until June 1, 2023. Reference lists of relevant papers were also cross-examined for other papers not detected in the initial search.
Results: Our literature search yielded 38 relevant papers. AI has been identified as a key component in digital health technologies. Within this field, there is the potential to apply specific techniques such as machine learning and deep learning to address several aspects of managing psoriatic disease. This includes diagnosis, particularly useful for remote teledermatology via photographs taken by patients as well as monitoring and estimating severity. Similarly, AI can be used to synthesize the vast data sets already in place through patient registries which can help identify appropriate biologic treatments for future cohorts and those individuals most likely to develop complications.
Conclusions: There are multiple advantageous uses for AI and digital health technologies in psoriatic disease. With wider implementation of AI, we need to be mindful of potential limitations, such as validation and standardization or generalizability of results in specific populations, such as patients with darker skin phototypes.
{"title":"AI in Psoriatic Disease: Scoping Review.","authors":"Richard Barlow, Anthony Bewley, Maria Angeliki Gkini","doi":"10.2196/50451","DOIUrl":"10.2196/50451","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) has many applications in numerous medical fields, including dermatology. Although the majority of AI studies in dermatology focus on skin cancer, there is growing interest in the applicability of AI models in inflammatory diseases, such as psoriasis. Psoriatic disease is a chronic, inflammatory, immune-mediated systemic condition with multiple comorbidities and a significant impact on patients' quality of life. Advanced treatments, including biologics and small molecules, have transformed the management of psoriatic disease. Nevertheless, there are still considerable unmet needs. Globally, delays in the diagnosis of the disease and its severity are common due to poor access to health care systems. Moreover, despite the abundance of treatments, we are unable to predict which is the right medication for the right patient, especially in resource-limited settings. AI could be an additional tool to address those needs. In this way, we can improve rates of diagnosis, accurately assess severity, and predict outcomes of treatment.</p><p><strong>Objective: </strong>This study aims to provide an up-to-date literature review on the use of AI in psoriatic disease, including diagnostics and clinical management as well as addressing the limitations in applicability.</p><p><strong>Methods: </strong>We searched the databases MEDLINE, PubMed, and Embase using the keywords \"AI AND psoriasis OR psoriatic arthritis OR psoriatic disease,\" \"machine learning AND psoriasis OR psoriatic arthritis OR psoriatic disease,\" and \"prognostic model AND psoriasis OR psoriatic arthritis OR psoriatic disease\" until June 1, 2023. Reference lists of relevant papers were also cross-examined for other papers not detected in the initial search.</p><p><strong>Results: </strong>Our literature search yielded 38 relevant papers. AI has been identified as a key component in digital health technologies. Within this field, there is the potential to apply specific techniques such as machine learning and deep learning to address several aspects of managing psoriatic disease. This includes diagnosis, particularly useful for remote teledermatology via photographs taken by patients as well as monitoring and estimating severity. Similarly, AI can be used to synthesize the vast data sets already in place through patient registries which can help identify appropriate biologic treatments for future cohorts and those individuals most likely to develop complications.</p><p><strong>Conclusions: </strong>There are multiple advantageous uses for AI and digital health technologies in psoriatic disease. With wider implementation of AI, we need to be mindful of potential limitations, such as validation and standardization or generalizability of results in specific populations, such as patients with darker skin phototypes.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e50451"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mindy D Szeto, Melissa R Laughter, Mayra B C Maymone, Payal M Patel, Torunn E Sivesind, Colby L Presley, Steven M Lada, Kayd J Pulsipher, Henriette De La Garza, Robert P Dellavalle
Unlabelled: Analyses of women dermatology literature authorship from 2018 to 2022 reveal a slight increase in total female authors, female first authors, and female senior authors with no substantial immediate impact of COVID-19 on current trends, encouraging future examination of long-term effects and ongoing promotion of systemic initiatives to support gender equity.
{"title":"Gender Representation in Authorship of Academic Dermatology Publications During the COVID-19 Pandemic: Cross-Sectional Study.","authors":"Mindy D Szeto, Melissa R Laughter, Mayra B C Maymone, Payal M Patel, Torunn E Sivesind, Colby L Presley, Steven M Lada, Kayd J Pulsipher, Henriette De La Garza, Robert P Dellavalle","doi":"10.2196/50396","DOIUrl":"10.2196/50396","url":null,"abstract":"<p><strong>Unlabelled: </strong>Analyses of women dermatology literature authorship from 2018 to 2022 reveal a slight increase in total female authors, female first authors, and female senior authors with no substantial immediate impact of COVID-19 on current trends, encouraging future examination of long-term effects and ongoing promotion of systemic initiatives to support gender equity.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"7 ","pages":"e50396"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}